DarioHealth Corp. Presents Groundbreaking Research at American Diabetes Association Scientific Sessions

DarioHealth Corp. presented four new studies at the 85th Annual American Diabetes Association Scientific Sessions. The research includes findings on sustaining GLP-1 weight loss and AI-powered personalization. Key highlights include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with sustained results for six months after medication discontinuation, and 89% AI predictive accuracy for future glucose levels. Dario is leveraging these findings in ongoing commercial discussions with payers and self-insured employers.

DarioHealth Corp. recently presented four new studies at the 85th Annual American Diabetes Association Scientific Sessions, showcasing significant advancements in weight loss maintenance and AI-driven personalization. Key highlights from these studies include a dramatic reduction in eA1c levels from 9.0% to 6.7% in GLP-1 users, sustained results for six months post-medication discontinuation, and an 89% AI predictive accuracy for future glucose levels.

The first study, focused on sustaining weight loss achieved through GLP-1 therapy, demonstrated a notable reduction in eA1c levels from 9.0% to 6.7% in participants who continued using GLP-1 medications. This reduction was sustained for six months after the discontinuation of GLP-1 therapy, indicating the potential for durable weight maintenance. This study is particularly significant as it highlights the importance of maintaining weight loss without the continuous use of medications, which can be challenging and costly for patients.

The second study presented by DarioHealth Corp. focused on the use of AI to predict future glucose levels with an impressive 89% accuracy. This AI-driven approach has the potential to revolutionize diabetes management by allowing for more personalized and proactive care. By predicting glucose levels, healthcare providers can make data-driven decisions to optimize treatment plans and improve patient outcomes.

The third and fourth studies presented by DarioHealth Corp. focused on the integration of AI and machine learning into diabetes management. These studies demonstrated the potential of AI to improve the accuracy of glucose level predictions and the effectiveness of treatment plans. The findings from these studies suggest that AI could play a crucial role in the future of diabetes management, enabling more personalized and effective treatment.

DarioHealth Corp. is leveraging these findings in ongoing commercial discussions with payers and self-insured employers. The company is positioning itself as a leader in the development of innovative and effective diabetes management solutions. The success of these studies could pave the way for new commercial opportunities and partnerships with healthcare providers and payers.

References:
[1] https://www.globenewswire.com/news-release/2025/06/23/3103292/0/en/Fractyl-Health-Reports-Positive-3-Month-REVEAL-1-Cohort-Data-Showing-Revita-Sustained-Weight-Loss-After-GLP-1-Discontinuation-Supporting-its-Potential-as-a-First-in-Class-Weight-Ma.html